Introduction
Myeloproliferative neoplasms (MPN) JAK2 mediates cytokine signaling from erythropoietin, thrombopoietin and GM-CSF receptors 11 . Germline deletion of Jak2 causes embryonic lethality by deficient definitive erythropoiesis 12,13 , which was confirmed by a conditional Jak2 allele and germline Crerecombinase 14 . Conditional Jak2 loss in hematopoietic stem/progenitor cells induces anemia and thrombocytopenia 15, 16 , while deletion of Mpl in platelets leads to thrombocytosis [17] [18] [19] . Although these studies highlight the significance of Jak-Stat signaling for steady state hematopoiesis, the specific requirement for Jak2 in different terminally differentiated myeloid lineages, including platelets, has not been clarified. We therefore investigated the effects of platelet-specific Jak2 loss in vivo. Technologies) with stem cell factor, IL-3, IL-6 and erythropoietin. Thrombopoietin was determined by Quantikine ELISA (R&D) in serum, or in media 22 incubated with purified platelets.
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Results and Discussion
To assess the requirement for Jak2 in platelets, we deleted Jak2 in platelets and megakaryocytes using Cre-recombinase expressed under the Pf4 promoter 14, 19, 20, 23 . Pf4-Cre-positive Jak2 f/f mice showed loss of Jak2 mRNA expression in platelets and megakaryocytes demonstrating complete excision, and we observed a modest reduction in Jak2 mRNA expression in megakaryocyte progenitors (MkP, p=0.029) (Fig.1A ). Jak2 mRNA expression was unaffected in megakaryocyte-erythroid progenitors (Pre-MegE)
or Lin -Sca1 + Kit + cells (LSK) (n=3-6 mice/group). Western blot analysis revealed loss of Jak2 protein expression in Pf4-Cre-positive Jak2 f/f platelets, despite continued Mpl expression ( Fig.1B-C) . Jak2 deletion in platelets abrogated Jak2, Stat3, Stat5 and Tyk2 phosphorylation upon Tpo stimulation (Fig.1D ). The absence of residual Tyk2 phosphorylation was consistent with cell line studies suggesting that Tpo-mediated activation of Tyk2 requires Jak2 24 .
We next investigated the impact of platelet-specific Jak2 deletion in vivo. Pf4-Crepositive Jak2 f/f mice developed thrombocytosis with average platelets of 4720 G/l (range 3436-6460 G/l, p<0.0001) at 2 months and 5966 G/l (3204-7892 G/l, p<0.0001) at 5 months of age (Fig.1E , n=5-17 mice/group). Platelet survival assessed by in vivo biotinylation and platelet volume were normal in Pf4-Cre-positive Jak2 f/f mice compared to littermate controls (Fig.1E ). Platelet-specific Jak2 loss resulted in leukocytosis with a mean white blood cell count of 23.7 G/l (vs. 11.9 G/l in controls, p=0.005) with proportionate expansion of all leukocyte subsets ( Fig.1F-G) . Hematocrit levels were not significantly affected. Platelet-specific Jak2 haploinsufficiency had no impact on blood counts compared to controls. These data demonstrate that Jak2 expression and activity in platelets are not required for terminal platelet production.
The thrombocytosis observed in Pf4-Cre-positive Jak2 f/f mice suggested platelet/megakaryocyte-specific Jak2 deletion led to non-autonomous expansion of Jak2-expressing stem/progenitor cells. Pf4-Cre-positive Jak2 f/f mice had expansion of Pre-MegE (209% of controls, p<0.0001), MkP (932% of controls, p=0.0001) and megakaryocytes (Mk, 606% of controls, p<0.0001) ( Fig.2A /D, n=3-12 mice/group).
Histopathologic analysis confirmed bone marrow megakaryocytosis (Fig.2B ).
Megakaryocyte colony formation from Pf4-Cre-positive Jak2 f/f bone marrow and sorted
For personal use only. on July 16, 2017. by guest www.bloodjournal.org From Pre-MegE or MkP was enhanced (Fig.2C) . We observed an increase in CFU-GEMM and CFU-GM colonies but not BFU-E colonies from Pf4-Cre-positive Jak2 f/f mice ( Fig.S1A-B ). These data demonstrate that platelet/megakaryocyte-specific Jak2 loss induces expansion of megakaryopoiesis in vivo.
We next assessed the impact of platelet-specific Jak2 loss on hematopoietic stem/progenitor cells in vivo. We observed a significant expansion in LSK number (567% of controls, p<0.0001, Fig.2E , n=5-11 mice/group). LSK cells from Pf4-Crepositive Jak2 f/f mice showed enhanced CFU-GEMM and CFU-GM colony formation ( Fig.S1C ) and marked expansion in megakaryocytic colony formation on a per-cell basis (Fig.2F) . This suggested the possibility that Pf4-Cre-positive Jak2 f/f mice had selective expansion of megakaryocyte-"primed" stem cells. (Fig.2I , n=8-13 mice/group). Jak2-deficient platelets internalized less Tpo than platelets from Pf4-Cre-negative Jak2 f/f controls (ΔTpo 884 pg/ml vs. 1051 pg/ml, p<0.01, Fig.2L ). Mpl mRNA expression was unchanged in megakaryocytes of Pf4-Cre-positive Jak2 f/f mice ( Fig.1A) , while Mpl total and surface protein was modestly reduced in Jak2-deficient platelets ( Fig.1C/2K ). These data suggest that Tpo levels are maintained at an inappropriately high rheostat in Pf4-Cre-positive Jak2 f/f mice due to reduced Tpo internalization by Jak2-deficient platelets.
In conclusion, our data demonstrate that Jak2 is dispensable for the production of megakaryocytes and platelets. This finding suggests that thrombocytopenia observed with certain JAK2 inhibitors is due to JAK2 inhibition in more proximal stem/progenitor cells consistent with conditional Jak2 knockout studies in hematopoiesis 15, 16 , or potentially due to inhibition of other targets. Analogous to genetic Jak2 loss, Jak2 inhibition in platelets/megakaryocytes may actually enhance platelet production 30 
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